Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

ALSUntangled #67: rituximab. Amyotroph Lateral Scler Frontotemporal Degener 2023 Aug;24(5-6):544-547

Date

09/16/2022

Pubmed ID

36106861

DOI

10.1080/21678421.2022.2122845

Scopus ID

2-s2.0-85138163435 (requires institutional sign-in at Scopus site)   2 Citations

Abstract

ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.

Author List

Li X, Armon C, Barkhaus P, Barnes B, Benatar M, Bertorini T, Bromberg M, Carter GT, Crayle J, Cudkowicz M, Dimachkie M, Feldman EL, Glass J, Goslinga J, Heiman-Patterson T, Jhooty S, Lichtenstein R, Lund I, Mcdermott C, Pattee G, Pierce K, Ratner D, Salmon K, Wicks P, Bedlack R

Author

Paul E. Barkhaus MD Professor in the Neurology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Amyotrophic Lateral Sclerosis
Humans
Off-Label Use
Rituximab